32,470 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the third quarter, Holdings Channel reports. The fund acquired 32,470 shares of the biopharmaceutical company’s stock, valued at approximately $759,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its stake in shares of TG Therapeutics by 24.7% in the third quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company’s stock worth $764,000 after buying an additional 6,467 shares in the last quarter. Entropy Technologies LP acquired a new position in shares of TG Therapeutics during the 3rd quarter worth approximately $730,000. Los Angeles Capital Management LLC grew its position in shares of TG Therapeutics by 33.7% in the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company’s stock valued at $2,886,000 after purchasing an additional 31,124 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Finally, Amalgamated Bank lifted its position in TG Therapeutics by 712.0% during the third quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 34,660 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $30.32 on Wednesday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market cap of $4.72 billion, a P/E ratio of -303.17 and a beta of 2.19. The firm’s 50 day moving average price is $25.00 and its 200-day moving average price is $21.35. TG Therapeutics, Inc. has a one year low of $11.86 and a one year high of $36.50.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the company earned $0.73 earnings per share. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of a number of recent research reports. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. B. Riley lifted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright increased their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.50% of the stock is owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.